GO:0014898 cardiac muscle hypertrophy in response to stress: Stress-Responsive Hypertrophy, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0014898 describes the enlargement of cardiac muscle fibers in response to stress, without cell division, as a homeostatic disturbance.
• It encompasses both physiological (e.g., exercise-induced) and pathological (e.g., pressure overload) hypertrophy, which have distinct molecular and metabolic signatures.
• Key signaling pathways include mTOR, AMPK, and metabolic rewiring, with emerging roles for epigenetic regulators such as Dot1L and Nsun2.
• Non-myocyte cells, including resident macrophages and fibroblasts, actively modulate the hypertrophic response and associated fibrosis.
• Dysregulation of this process underlies heart failure, arrhythmias, and hypertrophic cardiomyopathy, making it a major therapeutic target.
• CRISPR-based models (knockout, knock-in, overexpression) are essential for dissecting causal genes and validating therapeutic targets in cardiac hypertrophy.
Description
Cardiac muscle hypertrophy in response to stress (GO:0014898) is a fundamental biological process whereby the heart enlarges its muscle mass in reaction to increased workload or homeostatic disturbance. This process involves an increase in the size, not the number, of individual cardiac muscle fibers, and occurs without cell division. It is a compensatory mechanism that initially maintains cardiac output but can become maladaptive, leading to heart failure. Understanding the molecular and cellular drivers of this process is critical for developing therapies for cardiovascular disease, the leading cause of death worldwide. The term encompasses both physiological hypertrophy, such as that induced by exercise, and pathological hypertrophy triggered by hypertension, myocardial infarction, or valvular disease. These two forms are regulated by distinct signaling pathways and metabolic programs, with physiological hypertrophy being reversible and beneficial, while pathological hypertrophy often progresses to fibrosis, dysfunction, and heart failure. Recent research has highlighted the importance of non-myocyte cells, epigenetic regulators, and metabolic remodeling in shaping the hypertrophic response, offering new avenues for therapeutic intervention.
cardiac muscle hypertrophy in response to stress At A Glance
| GO ID | GO:0014898 |
|---|---|
| GO term | cardiac muscle hypertrophy in response to stress |
| Ontology | biological_process |
| Synonym | none |
| Major function | Compensatory enlargement of cardiac muscle fibers in response to stress, without cell division |
| Related processes | Cardiac muscle hypertrophy, response to stress, regulation of cell size |
| Cell types involved | Cardiomyocytes, cardiac fibroblasts, resident macrophages, endothelial cells |
| Key signaling pathways | mTOR, AMPK, MAPK, PI3K/Akt, metabolic rewiring |
| Disease relevance | Heart failure, hypertrophic cardiomyopathy, hypertension, myocardial infarction |
What Is GO:0014898?
According to the Gene Ontology, GO:0014898 is defined as the physiological enlargement or overgrowth of all or part of the heart muscle due to an increase in size (not length) of individual cardiac muscle fibers, without cell division, as a result of a disturbance in organismal or cellular homeostasis. In simpler terms, it is the heart's way of growing bigger in response to stress by making individual muscle cells larger, not by making more cells.
Why Is cardiac muscle hypertrophy in response to stress Important in Cell Biology?
Cardiac muscle hypertrophy in response to stress is a central adaptive and maladaptive process in cardiovascular biology. It represents the heart's primary mechanism to cope with increased workload, but when sustained, it leads to heart failure, arrhythmias, and sudden death. Understanding its molecular underpinnings is essential for identifying therapeutic targets and biomarkers. The process involves complex crosstalk between cardiomyocytes and non-myocyte cells, metabolic reprogramming, and epigenetic regulation, making it a rich area for research.
• It is a major compensatory mechanism for maintaining cardiac output under stress.
• Physiological hypertrophy is beneficial and reversible, while pathological hypertrophy is maladaptive and progresses to heart failure.
• Dysregulation of hypertrophy contributes to hypertrophic cardiomyopathy, hypertension, and post-infarction remodeling.
• Metabolic rewiring, including changes in fatty acid oxidation and glucose metabolism, is a hallmark of pathological hypertrophy.
• Epigenetic regulators such as Dot1L and Nsun2 are emerging as critical modulators of the hypertrophic response.
• Non-myocyte cells, including resident macrophages and fibroblasts, influence hypertrophy and fibrosis.
• Dysferlin-mediated membrane remodeling is required for cardiomyocyte growth during hypertrophy.
• The process is a key target for drug discovery, with many signaling pathways amenable to pharmacological intervention.
• CRISPR-based gene editing enables precise dissection of causal genes in hypertrophy models.
• Biomarkers of hypertrophy, such as circulating microRNAs and proteins, are being explored for clinical diagnosis.
What Happens During cardiac muscle hypertrophy in response to stress?
Stress Sensing and Initiation
In simple terms: The heart senses stress, such as high blood pressure or exercise, and starts a growth program.
Cardiac hypertrophy is initiated when cardiomyocytes sense mechanical, neurohumoral, or metabolic stress. This triggers intracellular signaling cascades, including the activation of G-protein-coupled receptors, integrins, and stretch-sensitive channels. Key early events include the release of angiotensin II, endothelin-1, and catecholamines, which activate downstream kinases such as protein kinase C and MAPKs. The initial response aims to normalize wall stress and maintain cardiac output. Recent studies have shown that metabolic sensors like AMPK and mTOR are rapidly engaged to coordinate energy supply with growth demands.
Transcriptional and Epigenetic Reprogramming
In simple terms: The cell changes which genes are turned on or off to support growth.
Stress signals activate transcription factors such as GATA4, MEF2, NFAT, and SRF, which drive the expression of fetal genes and structural proteins. Epigenetic modifications, including histone methylation and DNA methylation, play critical roles. For instance, Dot1L, a histone H3K79 methyltransferase, promotes stress-induced cardiac hypertrophy via Tbx6. Similarly, Nsun2, an RNA methyltransferase, controls cardiac homeostasis and hypertrophic response by regulating PRKACA expression. These epigenetic regulators fine-tune the transcriptional output necessary for hypertrophic growth.
Metabolic Rewiring
In simple terms: The heart switches its fuel sources to meet the high energy demand of growth.
During hypertrophy, the heart undergoes metabolic reprogramming, shifting from fatty acid oxidation to glucose utilization, similar to the fetal metabolic profile. This switch is mediated by changes in the expression and activity of key metabolic enzymes and regulators such as PGC-1α, PPARα, and AMPK. While initially adaptive, sustained metabolic remodeling can lead to energy deficit and contractile dysfunction. Recent research highlights the importance of amino acid metabolism and mitochondrial dynamics in this process.
Cardiomyocyte Growth and Structural Remodeling
In simple terms: Individual heart muscle cells get bigger and reorganize their internal structures.
The hallmark of hypertrophy is an increase in cardiomyocyte size, achieved through enhanced protein synthesis and sarcomere assembly. This requires coordinated regulation of translation, autophagy, and membrane remodeling. Dysferlin, a membrane protein, enables tubular membrane proliferation essential for cardiomyocyte growth during hypertrophy. The cytoskeleton and sarcomere are reorganized, with increased expression of fetal isoforms of contractile proteins. This structural remodeling is supported by angiogenesis and extracellular matrix changes.
Non-Myocyte Contributions and Fibrosis
In simple terms: Other cells in the heart, like immune cells and fibroblasts, help or hinder the growth process.
Cardiac hypertrophy is not solely a cardiomyocyte phenomenon. Resident macrophages prevent fibrosis and stimulate angiogenesis, thereby supporting adaptive hypertrophy. However, in pathological hypertrophy, fibroblasts become activated and deposit excessive collagen, leading to fibrosis and stiffness. High-resolution transcriptomic profiling has revealed cellular drivers of fibrosis and hypertrophy, including distinct fibroblast and macrophage subpopulations. The balance between adaptive and maladaptive non-myocyte responses determines the outcome of hypertrophy.
Key Genes Involved in GO:0014898 cardiac muscle hypertrophy in response to stress
The following genes and proteins are key players in cardiac muscle hypertrophy in response to stress, as supported by recent literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| MTOR | Central kinase regulating protein synthesis and cell growth | Target for hypertrophy inhibition; knockout models show blunted hypertrophy |
| AMPK | Energy sensor; regulates metabolic adaptation | Activation limits pathological hypertrophy; knockout worsens dysfunction |
| DOT1L | Histone methyltransferase; epigenetic regulator | Promotes stress-induced hypertrophy via Tbx6; knockout attenuates hypertrophy |
| NSUN2 | RNA methyltransferase; regulates PRKACA expression | Controls cardiac homeostasis; knockout leads to hypertrophy and dysfunction |
| PRKACA | Catalytic subunit of PKA; regulates contractility and gene expression | Target of Nsun2; overexpression mimics hypertrophy |
| TBX6 | Transcription factor; downstream of Dot1L | Mediates Dot1L-induced hypertrophy; knockout reduces hypertrophy |
| DYSF | Membrane protein; enables tubular membrane proliferation | Required for cardiomyocyte growth; mutations cause muscular dystrophy with cardiomyopathy |
| GATA4 | Transcription factor; drives fetal gene program | Overexpression induces hypertrophy; knockout impairs hypertrophy |
| MEF2 | Transcription factor; regulates sarcomere genes | Target of hypertrophic signaling; knockout blocks hypertrophy |
| NFATC1 | Transcription factor; calcineurin pathway | Dephosphorylation and nuclear import drive hypertrophy; knockout reduces hypertrophy |
| SRF | Transcription factor; serum response factor | Regulates cytoskeletal and contractile genes; knockout is embryonic lethal |
| PPARGC1A | Transcriptional coactivator; mitochondrial biogenesis | Downregulation contributes to metabolic remodeling; overexpression protects |
| PPARA | Nuclear receptor; fatty acid oxidation | Downregulation in hypertrophy; knockout worsens metabolic stress |
| CD68 | Macrophage marker; resident macrophages | Macrophage depletion exacerbates fibrosis; relevant for non-myocyte studies |
| COL1A1 | Collagen type I; fibrosis | Upregulated in pathological hypertrophy; target for anti-fibrotic therapy |
| VEGFA | Angiogenesis; endothelial growth factor | Macrophages stimulate angiogenesis via VEGFA; knockout impairs hypertrophy |
| ACTA1 | Sarcomeric actin; contractile protein | Fetal isoform re-expressed in hypertrophy; marker of remodeling |
| MYH7 | Beta-myosin heavy chain; contractile protein | Upregulated in pathological hypertrophy; mutations cause cardiomyopathy |
How Is cardiac muscle hypertrophy in response to stress Regulated?
Cardiac muscle hypertrophy in response to stress is regulated by a complex network of signaling pathways, transcription factors, and epigenetic modifiers. The mTOR pathway integrates growth factor and nutrient signals to promote protein synthesis, while AMPK acts as an energy sensor to restrain energy-consuming processes. Epigenetic regulators such as Dot1L and Nsun2 modulate gene expression programs essential for hypertrophy. Non-coding RNAs, including microRNAs and long non-coding RNAs, also fine-tune the hypertrophic response. Additionally, metabolic intermediates such as acetyl-CoA and NAD+ influence chromatin state and gene expression, linking metabolism to epigenetic regulation. The interplay between these regulatory layers determines whether hypertrophy remains adaptive or transitions to maladaptive.
cardiac muscle hypertrophy in response to stress and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| MYH7 | Hypertrophic cardiomyopathy | Knock-in mouse model with MYH7 mutation; CRISPR point mutation in iPSC-derived cardiomyocytes |
| DOT1L | Heart failure; pathological hypertrophy | Cardiomyocyte-specific knockout mouse; overexpression via AAV |
| NSUN2 | Cardiac homeostasis; hypertrophy | Knockout mouse; point mutation in catalytic domain |
| DYSF | Muscular dystrophy with cardiomyopathy | Knockout mouse; knock-in of human mutation |
| PRKACA | Hypertrophy; contractile dysfunction | Overexpression mouse; CRISPR activation in cardiomyocytes |
Heart Failure
Sustained pathological cardiac hypertrophy is a major risk factor for heart failure. Maladaptive hypertrophy leads to ventricular dilation, contractile dysfunction, and fibrosis, ultimately impairing the heart's ability to pump blood. Metabolic remodeling and energy deficit contribute to disease progression. Targeting the molecular drivers of hypertrophy, such as mTOR and epigenetic regulators, is a promising therapeutic strategy.
Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy (HCM) is a genetic disorder characterized by unexplained left ventricular hypertrophy. Mutations in sarcomere genes such as MYH7 and ACTA1 are common causes. The disease often presents with arrhythmias and sudden cardiac death. Understanding the hypertrophic response at the molecular level is crucial for developing gene-specific therapies.
Hypertension and Valvular Disease
Chronic hypertension and aortic stenosis impose pressure overload on the heart, triggering compensatory hypertrophy that frequently becomes pathological. This form of hypertrophy is associated with increased fibrosis and diastolic dysfunction. Non-myocyte cells, particularly macrophages and fibroblasts, play key roles in the maladaptive remodeling process.
Metabolic Cardiomyopathies
Disorders of metabolism, such as diabetes and obesity, can induce cardiac hypertrophy through metabolic stress. The heart's inability to adapt metabolically leads to lipotoxicity and insulin resistance, exacerbating hypertrophy and dysfunction. Targeting metabolic pathways may offer therapeutic benefits in these conditions.
From cardiac muscle hypertrophy in response to stress-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X drive pathological hypertrophy? | Cardiomyocyte-specific knockout mouse (e.g., Dot1L fl/fl; Myh6-Cre) |
| Does a specific point mutation in gene Y cause hypertrophy? | Knock-in mouse or iPSC-derived cardiomyocytes with CRISPR-edited mutation |
| Can overexpression of gene Z induce hypertrophy? | AAV-mediated overexpression in mouse heart or transgenic mouse |
| What is the role of gene W in non-myocyte cells? | Macrophage-specific knockout or fibroblast-specific knockout |
| How does metabolic gene V affect hypertrophy? | Inducible knockout or overexpression in adult mouse heart |
| Can CRISPR screening identify novel hypertrophy regulators? | Pooled CRISPR knockout screen in primary cardiomyocytes or iPSC-derived cardiomyocytes |
How to Study the cardiac muscle hypertrophy in response to stress Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify differentially expressed genes in hypertrophy models |
| Single-cell RNA-seq | Cell-type-specific transcriptomes | Dissect non-myocyte contributions to hypertrophy |
| ChIP-seq | Histone modifications and transcription factor binding | Map Dot1L-mediated H3K79 methylation |
| MeRIP-seq | RNA methylation (m6A, m5C) | Study Nsun2-mediated RNA methylation |
| Proteomics | Protein abundance and modifications | Quantify metabolic enzyme changes |
| Metabolomics | Metabolic intermediates | Assess metabolic rewiring |
| Echocardiography | Cardiac structure and function | Monitor hypertrophy progression in mice |
| Confocal microscopy | Cardiomyocyte size and sarcomere organization | Visualize hypertrophy in vitro and in vivo |
Transcriptomic Profiling
RNA sequencing (RNA-seq) of cardiac tissue or isolated cardiomyocytes at different stages of hypertrophy reveals dynamic changes in gene expression. Single-cell RNA-seq has been instrumental in identifying cellular drivers of fibrosis and hypertrophy, such as distinct fibroblast and macrophage subpopulations. This method provides a comprehensive view of the transcriptional landscape and can uncover novel regulators.
Epigenomic and Epitranscriptomic Analysis
Techniques such as ChIP-seq, ATAC-seq, and RNA immunoprecipitation (RIP) are used to study epigenetic modifications. For example, Dot1L-mediated H3K79 methylation can be mapped by ChIP-seq, and Nsun2-mediated RNA methylation can be detected by MeRIP-seq. These methods reveal how epigenetic and epitranscriptomic changes contribute to hypertrophy.
Proteomics and Metabolomics
Mass spectrometry-based proteomics and metabolomics quantify changes in protein abundance and metabolic intermediates during hypertrophy. These approaches have highlighted the importance of metabolic rewiring, including shifts in fatty acid oxidation and glucose metabolism. They can also identify post-translational modifications critical for signaling.
Imaging and Functional Assessment
Echocardiography, cardiac MRI, and histology are used to assess cardiac structure and function in animal models. Confocal and electron microscopy can visualize cardiomyocyte size, sarcomere organization, and membrane structures such as T-tubules, which are remodeled during hypertrophy. These methods provide direct evidence of hypertrophic growth and dysfunction.
How CRISPR Can Be Used to Study GO:0014898 cardiac muscle hypertrophy in response to stress
Knockout
CRISPR-Cas9 knockout is widely used to study loss-of-function of candidate genes in cardiac hypertrophy. For example, cardiomyocyte-specific knockout of Dot1L attenuated stress-induced hypertrophy in mice. Knockout of Nsun2 led to cardiac dysfunction and hypertrophy. These models help establish causality and identify essential genes.
Point Mutation
CRISPR-mediated point mutations can mimic human disease variants or disrupt specific protein functions. For instance, introducing a catalytic-dead mutation in Dot1L or Nsun2 can dissect the importance of enzymatic activity versus scaffolding functions. Point mutations in sarcomere genes like MYH7 are used to model hypertrophic cardiomyopathy.
Knock-in
Knock-in of reporter genes or epitope tags allows visualization and purification of proteins. Tagging endogenous Dot1L or Nsun2 with fluorescent proteins enables live-cell imaging and chromatin immunoprecipitation. Knock-in of human disease mutations into mouse models provides more accurate disease modeling.
Overexpression
CRISPR activation (CRISPRa) or AAV-mediated overexpression can drive gene expression to study gain-of-function. Overexpression of PRKACA in cardiomyocytes induced hypertrophy, and overexpression of Tbx6 mimicked Dot1L effects. These models are useful for identifying sufficiency of a gene to drive hypertrophy.
How EDITGENE Supports cardiac muscle hypertrophy in response to stress Research
Researchers studying cardiac muscle hypertrophy in response to stress-related genes often need to determine whether a candidate gene is causally involved in the hypertrophic response or merely a bystander. This requires precise genetic manipulation in relevant cell types and animal models. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this discovery process.
Contact EDITGENE today to design your custom CRISPR model for cardiac muscle hypertrophy in response to stress research.
Frequently Asked Questions About cardiac muscle hypertrophy in response to stress
What is cardiac muscle hypertrophy in response to stress?
It is the enlargement of heart muscle fibers in response to stress, without cell division, as defined by GO:0014898.
What genes are involved in cardiac muscle hypertrophy in response to stress?
Key genes include MTOR, AMPK, DOT1L, NSUN2, PRKACA, TBX6, DYSF, GATA4, MEF2, and NFATC1, among others.
How is cardiac hypertrophy different from physiological hypertrophy?
Physiological hypertrophy is reversible and beneficial, while pathological hypertrophy is maladaptive and leads to heart failure.
What signaling pathways regulate cardiac hypertrophy?
mTOR, AMPK, MAPK, PI3K/Akt, and calcineurin pathways are major regulators.
What is the role of Dot1L in cardiac hypertrophy?
Dot1L, a histone methyltransferase, promotes stress-induced hypertrophy via Tbx6.
How does Nsun2 affect the heart?
Nsun2 controls cardiac homeostasis and hypertrophic response by regulating PRKACA expression.
What are the metabolic changes in cardiac hypertrophy?
The heart shifts from fatty acid oxidation to glucose utilization, similar to fetal metabolism.
What cell types are involved in cardiac hypertrophy?
Cardiomyocytes, fibroblasts, resident macrophages, and endothelial cells all contribute.
What diseases are associated with cardiac hypertrophy?
Heart failure, hypertrophic cardiomyopathy, hypertension, and valvular disease.
How can CRISPR be used to study cardiac hypertrophy?
CRISPR knockout, point mutation, knock-in, and overexpression models enable precise genetic dissection of hypertrophy pathways.
Conclusion
Cardiac muscle hypertrophy in response to stress (GO:0014898) is a complex biological process with profound implications for cardiovascular health and disease. Recent advances have illuminated the roles of epigenetic regulators, metabolic rewiring, and non-myocyte cells in shaping the hypertrophic response. Continued research using CRISPR-based models and multi-omics approaches will further unravel the molecular mechanisms and identify new therapeutic targets. EDITGENE is committed to supporting this research with state-of-the-art gene editing services.
References
- 1. Nakamura M et al.. 2018. Mechanisms of physiological and pathological cardiac hypertrophy.. Nat Rev Cardiol 15(7):387-407 PMID: 29674714
- 2. Ritterhoff J et al.. 2023. Metabolic mechanisms in physiological and pathological cardiac hypertrophy: new paradigms and challenges.. Nat Rev Cardiol 20(12):812-829 PMID: 37237146
- 3. Liu J et al.. 2025. Dot1L Promotes Stress-Induced Cardiac Hypertrophy in Mice via Tbx6.. Circ Res 137(4):496-512 PMID: 40583756
- 4. Bazgir F et al.. 2023. The Microenvironment of the Pathogenesis of Cardiac Hypertrophy.. Cells 12(13) PMID: 37443814
- 5. Revelo XS et al.. 2021. Cardiac Resident Macrophages Prevent Fibrosis and Stimulate Angiogenesis.. Circ Res 129(12):1086-1101 PMID: 34645281
- 6. Paulke NJ et al.. 2024. Dysferlin Enables Tubular Membrane Proliferation in Cardiac Hypertrophy.. Circ Res 135(5):554-574 PMID: 39011635
- 7. McLellan MA et al.. 2020. High-Resolution Transcriptomic Profiling of the Heart During Chronic Stress Reveals Cellular Drivers of Cardiac Fibrosis and Hypertrophy.. Circulation 142(15):1448-1463 PMID: 32795101
- 8. Jian D et al.. 2025. Nsun2 controls cardiac homeostasis and hypertrophic response by regulating PRKACA expression.. Theranostics 15(6):2393-2412 PMID: 39990213
